Showing 4981-4990 of 20470 results for "".
- Arcutis Launches First-in-Human Trial of CD200R Agonist ARQ-234 in Atopic Dermatitishttps://reachmd.com/news/arcutis-launches-first-in-human-trial-of-cd200r-agonist-arq-234-in-atopic-dermatitis/2485894/Arcutis Biotherapeutics announced today that it has enrolled the first participant in a phase 1a/1b clinical trial evaluating ARQ-234, an investigational CD200 receptor (CD200R) agonist, in healthy volunteers and adults with moderate to severe atopic dermatitis (AD
- Urine cfDNA EM-seq Ensemble Detects Bladder Cancer (AUC 0.932)https://reachmd.com/news/urine-cfdna-em-seq-ensemble-detects-bladder-cancer-auc-0932/2485859/Investigators describe a urine cfDNA EM-seq ensemble assay that pairs whole-genome enzymatic methylation sequencing (EM-seq) with an XGBoost-based approa
- WIF Centrality Links Burnout, Engagement, and After‑Hours Connectivity in University Teachershttps://reachmd.com/news/wif-centrality-links-burnout-engagement-and-afterhours-connectivity-in-university-teachers/2485864/Investigators reporting on a sample of 409 university teachers describe Work Interfering with Family (WIF) as a central, bridging node in a partial-corre
- EMA Panel Backs Baricitinib for Adolescents With Severe Alopecia Areatahttps://reachmd.com/news/ema-panel-backs-baricitinib-for-adolescents-with-severe-alopecia-areata/2485850/The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of baricitinib (Olumiant, Eli Lilly and Company), a once-daily oral Janus kinase (JAK) inhibitor, for adolescents aged 12 to yo
- AUA Releases GSM Guideline: Scope, Recommendations, and Care Domainshttps://reachmd.com/news/aua-releases-gsm-guideline-scope-recommendations-and-care-domains/2485874/The American Urological Association (AUA) recently released its Guideline on Genitourinary Sy
- Photocurable Collagen Filler Aims to Address Weight-Loss–Associated Facial Deflationhttps://reachmd.com/news/photocurable-collagen-filler-aims-to-address-weight-lossassociated-facial-deflation/2485851/CollPlant Biotechnologies announced the strategic positioning of its photocurable dermal filler platform to address facial volume loss associated with rapid weight reduction, including in patients treated with glucagon-like peptide-1 receptor agonists (GLP-1 RA) for metabolic health and weight ma
- WALANT vs Axillary Block for Dual‑Mobility TMC Prosthesishttps://reachmd.com/news/walant-vs-axillary-block-for-dualmobility-tmc-prosthesis/2485841/A small prospective observational cohort compared wide-awake local anesthesia no tourniquet (WALANT) with an ultrasound-guided axillary brachial plexus block during implantation of a dual‑mobility TMC
- 5-Day Accelerated TMS Showed Comparable Short-Term Relief for Many Patientshttps://reachmd.com/news/5-day-accelerated-tms-showed-comparable-short-term-relief-for-many-patients/2485842/A condensed, high-intensity five-day transcranial magnetic stimulation schedule—described as the “5x5 TMS protocol” (five sessions per day for five days)—wa
- Blood-Based Metabolite Signatures Reported for Gallbladder Cancerhttps://reachmd.com/news/blood-based-metabolite-signatures-reported-for-gallbladder-cancer/2485845/A blood-based chemical or metabolite “signature” is reported to distinguish gallbladder cancer from benign gallstone disease, including in
- Swedish Cohort: HPV Vaccination Linked to Sustained Protection up to 18 yearshttps://reachmd.com/news/swedish-cohort-hpv-vaccination-linked-to-sustained-protection-up-to-18-years/2485832/A recent report describes a nationwide, register-based analysis from Sweden that followed girls and women through 31 Dec 2023 and examined associations between human papillomavirus (HPV) vaccination history and subsequent invasive cervical cancer risk. Results are framed around two themes: